12 Million Lost GLP-1 Wegovy Zepbound Employer Coverage 2026: What to Do Now

# 12 Million Lost GLP-1 Wegovy Zepbound Employer Coverage 2026: What to Do Now

> **Quick answer:** In 2026, 12 million people lost employer insurance coverage for Wegovy and another 12 million lost Zepbound coverage as companies cut GLP-1 weight-loss benefits to control surging drug costs. Your five main options: manufacturer savings cards (Wegovy as low as $25/month with commercial insurance, $149/month without; Zepbound from $299/month via LillyDirect), compounding pharmacies (~$99/month), appealing your prior authorization denial (82% of appeals succeed), the diabetes indication route if your doctor can justify it, and — for Medicare-eligible patients — the July 1, 2026 Medicare GLP-1 Bridge at $50/month.

*This article is for informational purposes only and does not replace professional medical advice or constitute financial advice. Consult a qualified healthcare provider for decisions about your medications and a benefits advisor for coverage questions.*

If you opened your 2026 benefits summary and noticed that Wegovy or Zepbound were quietly removed from your formulary, you are in enormous company. GLP-1 Wegovy Zepbound coverage lost 2026 is one of the largest private insurance pullbacks in a decade — and unlike a deductible increase, this cut can mean the difference between affording a $1,000-per-month drug or not affording it at all.

This guide is specifically for patients who had employer-sponsored coverage and lost it. It explains what happened, why employers made this decision, and — most importantly — every concrete path available to you right now.

## What Happened: 12 Million People, Two Drugs, One Driving Force